公告提到，布瑞哌唑片的规格为1mg和2mg，主要用于治疗成人精神分裂症，注册分类为化学药品4 类。本次布瑞哌唑片获批上市，丰富了公司的产品管线。 近日，康弘药业（002773）发布公告称，公司近日收到国家药品监督管理局签发的布瑞哌唑片的《药品 注册证书》。布瑞哌唑用于治疗精神分裂症的作用机制尚不明确，可能是通过5-羟色胺 5-HT1A 和多巴 胺 D2 受体的部分激动剂活性、5-羟色胺 5-HT2A受体的拮抗剂活性联合介导。 ...

Group 1 - 德方纳米 plans annual equipment maintenance to ensure efficient and stable operation, starting January 1, 2026, for one month, with no significant impact on 2026 performance [1] - 达意隆's subsidiary Tianjin Baolong faces a significant decline in OEM orders due to strategic adjustments from core customers, leading to plans to shut down production lines [2] - 天威视讯's subsidiary plans to transfer project assets for 604.3 million yuan to a related party, constituting a related transaction [3] Group 2 - 金龙羽 intends to sign a strategic cooperation framework agreement with an investment institution to establish an industrial merger fund with a planned scale of 1.5 billion yuan [4] - 紫光国微's subsidiary plans to establish a new company with multiple partners, including a subsidiary of CATL, with a registered capital of 300 million yuan [5] - 信隆健康's major shareholder plans to reduce its stake by up to 1% through trading [6] Group 3 - 龙建股份 wins a 612 million yuan EPC contract for a project, which represents approximately 3.27% of the company's audited revenue for 2024 [7] - 复旦张江 receives acceptance for a clinical trial application for a drug aimed at visualizing malignant lesions in lung cancer patients [9] - 博实股份's major shareholder plans to reduce its stake by up to 2.93% [10] Group 4 - 百纳千成 plans to acquire 100% of Zhonglian Century's shares to expand its marketing business and digital advertising solutions [11] - 天铁科技's major shareholder is under criminal detention, but the investigation is unrelated to the company's operations [12] - 海看股份's shareholder plans to reduce its stake by up to 3.6% [13] Group 5 - 智光电气's subsidiary signs a procurement contract worth 148 million yuan for a high-voltage energy storage system [14] - 西藏矿业's attempt to transfer 100% of a subsidiary's equity has not attracted qualified buyers, leading to automatic withdrawal from the trading platform [15] - 英诺激光's major shareholder plans to reduce its stake by up to 3% [16] Group 6 - 福鞍股份's major shareholder plans to reduce its stake by up to 3% [17] - 白云山 receives a drug registration certificate for a rabies vaccine [18] - 华电科工 signs a contract worth approximately 265 million yuan for a power plant project [19] Group 7 - 康弘药业 receives a drug registration certificate for a medication used to treat schizophrenia [20] - 西菱动力's actual controller plans to reduce their stake by 2% [21] - 海希通讯's actual controller plans to reduce their stake by 0.48% [22] Group 8 - 海南机场 plans to transfer 90% of a subsidiary's equity for approximately 500 million yuan, expecting a profit of about 200 million yuan from the transaction [23] - 森远股份 signs a contract for a computing cluster integration project worth 26.78 million yuan [24] - 丽珠集团's subsidiary receives acceptance for a drug registration application for a new treatment for psoriasis [25] Group 9 - 郑州银行 plans to acquire a village bank and convert it into a branch [26] - 方正证券 announces a cash dividend distribution plan for the third quarter of 2025 [27] - 金陵体育 announces a cash dividend distribution plan for the first three quarters of 2025 [29] Group 10 - 紫金银行 announces a mid-term profit distribution plan for 2025 [30] - *ST建艺's major shareholder waives 1.4 billion yuan in debt and donates 400 million yuan to support the company [31] - 万朗磁塑's major shareholder plans to reduce their stake by up to 3% [32] Group 11 - 艾力斯's core product is included in a list of potential breakthrough therapies for lung cancer [33] - 富创精密's shareholder plans to transfer 918.63 million shares [34] - 东阳光's subsidiary plans to increase capital and introduce investors [35] Group 12 - 侨银股份 plans to acquire a 16.67% partnership in a venture capital fund [36] - 尤夫股份 receives a government subsidy of 4.04 million yuan for a technical improvement project [37] - 倍轻松 and its actual controller are under investigation for information disclosure violations [38] Group 13 - 万润新能 plans to reduce production on some lines for maintenance, expecting a reduction of 5,000 to 20,000 tons in lithium iron phosphate output [39]

每经AI快讯，康弘药业（SZ 002773，收盘价：31.17元）12月25日晚间发布公告称，成都康弘药业集团 股份有限公司于近日收到国家药品监督管理局签发的布瑞哌唑片的《药品注册证书》，批准注册。 2025年1至6月份，康弘药业的营业收入构成为：医药制造业占比99.97%，其他业务占比0.03%。 截至发稿，康弘药业市值为287亿元。 每经头条（nbdtoutiao）——对话马斯克脑机接口"一号受试者"：大脑植入芯片23个月，我正重新夺回 人生的独立 （记者 张明双） ...

格隆汇12月25日丨康弘药业(002773.SZ)公布，近日收到国家药品监督管理局签发的布瑞哌唑片的《药 品注册证书》（证书编号：2025S03922、2025S03923），批准注册。布瑞哌唑用于治疗精神分裂症的 作用机制尚不明确，可能是通过5-羟色胺 5-HT1A和多巴胺 D2受体的部分激动剂活性、5-羟色胺5- HT2A受体的拮抗剂活性联合介导。 ...

康弘药业(002773.SZ)发布公告，公司于近日收到国家药品监督管理局签发的布瑞哌唑片的《药品注册 证书》(证书编号：2025S03922、2025S03923)，批准注册。布瑞哌唑用于治疗精神分裂症的作用机制尚 不明确，可能是通过5-羟色胺5-HT1A和多巴胺D2受体的部分激动剂活性、5-羟色胺5-HT2A受体的拮抗 剂活性联合介导。 ...

康弘药业（002773）(002773.SZ)发布公告，公司于近日收到国家药品监督管理局签发的布瑞哌唑片的 《药品注册证书》(证书编号：2025S03922、2025S03923)，批准注册。布瑞哌唑用于治疗精神分裂症的 作用机制尚不明确，可能是通过5-羟色胺5-HT1A和多巴胺D2受体的部分激动剂活性、5-羟色胺5-HT2A 受体的拮抗剂活性联合介导。 ...

格隆汇12月25日丨康弘药业(002773.SZ)公布，近日收到国家药品监督管理局签发的布瑞哌唑片的《药 品注册证书》（证书编号：2025S03922、2025S03923），批准注册。布瑞哌唑用于治疗精神分裂症的 作用机制尚不明确，可能是通过5-羟色胺 5-HT1A和多巴胺 D2受体的部分激动剂活性、5-羟色胺5- HT2A受体的拮抗剂活性联合介导。 财经频道更多独家策划、专家专栏，免费查阅>>责任编辑：钟离 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-074 成都康弘药业集团股份有限公司 关于公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于近日收 到国家药品监督管理局签发的布瑞哌唑片的《药品注册证书》（证书 编号：2025S03922、2025S03923），批准注册。现将相关情况公告如 下： 批准文号：国药准字 H20256388、国药准字 H20256389 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二． 产品简介 1 / 2 布瑞哌唑用于治疗精神分裂症的作用机制尚不明确，可能是通过 5-羟色胺 5-HT1A和多巴胺 D2受体的部分激动剂活性、5-羟色胺 5-HT2A 受体的拮抗剂活性联合介导。 一． 药品基本信息 药品名称：布瑞哌唑片 剂型：片剂 规格：1mg、2mg 适应症：本品用于治疗成人精神分裂症。 注册分类：化学药品 4 类 三． 对公司的影响 本次布瑞哌唑片获批上市，丰富了 ...

每经AI快讯，12月25日，康弘药业（002773）(002773.SZ)公告称，公司于近日收到国家药品监督管理 局签发的布瑞哌唑片的《药品注册证书》，批准注册。该药品用于治疗成人精神分裂症，注册分类为化 学药品4类。此次获批丰富了公司的产品管线，但医药产品的生产销售情况可能受到市场环境变化等因 素影响，存在不确定性，投资者需谨慎决策。 ...

证券之星消息，12月25日生物制品板块较上一交易日上涨0.18%，金迪克领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688670 | 金克 | 22.45 | 4.66% | 6.68万 | 1.48亿 | | 688443 | 智翔金泰 | 27.07 | 3.08% | 3.78万 | 1.01亿 | | 000518 | *ST四环 | 2.46 | 2.93% | 10.92万 | 2642.85万 | | 000534 | 万泽股份 | 24.15 | 2.33% | 20.35万 | 4.88亿 | | 688520 | 神州细胞 | 44.55 | 1.71% | 2.72万 | 261T | | 301080 | 百普賽斯 | 55.23 | 1.56% | 1.40万 | 7720.60万 | | 002773 | 康弘药业 | 31.17 ...